PhRMA bangs US innovation drum by bashing foreign prices

10 May 2017

The leading pharma lobby group in the USA has been working to defend drug prices at home in recent months amid President Donald Trump’s tough talk about targeting drugmakers, but with a patriotic tone that could have come from the man himself, it has now criticized other countries for not paying adequately for US innovation.

Jay Taylor, vice president of international advocacy at Pharmaceutical and Research Manufacturers of America (PhRMA), has published a column arguing that government-imposed price controls in some parts of the world are threatening innovation and access.

"Other countries disproportionately reap our rewards, and global public health is threatened"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK